Literature DB >> 16926751

Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda.

Heiko Karcher1, Andrea Kunz, Gabriele Poggensee, Paulina Mbezi, Kizito Mugenyi, Gundel Harms.   

Abstract

OBJECTIVE: Prevention-of-mother-to-child transmission (PMTCT) interventions based on single-dose nevirapine (NVP) are widely implemented in Africa, but strategies differ regarding how and when to administer the drug to women and infants. The aim of this study was to analyze the outcome of different strategies with regard to NVP intake in pregnant women and their infants in Tanzania and Uganda.
METHODS: In an observational study carried out between March 2002 and December 2004, we compared a directly observed NVP administration strategy in Tanzania (supervised NVP intake for women and infants at a health unit) and a semi-observed administration strategy (self-administered NVP for women at home and supervised intake for infants at a health unit) in Uganda.
RESULTS: The proportions of HIV-positive women accepting receipt of NVP from the health units were similar in the 2 countries (42.4% in Tanzania vs 45.6% in Uganda; P = .06). NVP intake in infants was significantly higher in Tanzania than in Uganda (43.7% vs 24.1%; P > .001). In a multivariate analysis, maternal age above 25 years, secondary education, Catholic faith, and having undergone PMTCT counseling at a hospital were independently associated with infant NVP intake.
CONCLUSION: In our settings, the directly observed administration strategy resulted in a higher NVP intake in infants. The semi-observed strategy, which implies that, after home delivery, the infant has to be presented to a health unit for NVP administration, was less successful.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926751      PMCID: PMC1785187     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  22 in total

1.  High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting.

Authors:  M Manzi; R Zachariah; R Teck; L Buhendwa; J Kazima; E Bakali; P Firmenich; P Humblet
Journal:  Trop Med Int Health       Date:  2005-12       Impact factor: 2.622

2.  The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial.

Authors:  Isaac M Malonza; Barbra A Richardson; Joan K Kreiss; Job J Bwayo; Grace C Stewart
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

3.  Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya.

Authors:  James N Kiarie; Joan K Kreiss; Barbra A Richardson; Grace C John-Stewart
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

4.  Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.

Authors:  Jeffrey S A Stringer; Moses Sinkala; Julia P Stout; Robert L Goldenberg; Edward P Acosta; Victoria Chapman; Rosemary Kumwenda-Phiri; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-15       Impact factor: 3.731

5.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

6.  Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.

Authors:  Lynn Morris; Candice Pillay; Claudia Chezzi; Pumla Lupondwana; Matshediso Ntsala; Leon Levin; Francois Venter; Neil Martinson; Glenda Gray; James McIntyre
Journal:  AIDS       Date:  2003-07-25       Impact factor: 4.177

7.  Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.

Authors:  Coleen K Cunningham; Marie-Laure Chaix; Claire Rekacewicz; Paula Britto; Christine Rouzioux; Richard D Gelber; Alejandro Dorenbaum; Jean Francois Delfraissy; Brigitte Bazin; Lynne Mofenson; John L Sullivan
Journal:  J Infect Dis       Date:  2002-06-26       Impact factor: 5.226

8.  Mother-to-child HIV transmission in resource poor settings: how to improve coverage?

Authors:  Marleen Temmerman; Ann Quaghebeur; Fabian Mwanyumba; Kishor Mandaliya
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

9.  Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia.

Authors:  Elizabeth M Stringer; Moses Sinkala; Jeffrey S Stringer; Elizabeth Mzyece; Ida Makuka; Robert L Goldenberg; Pascal Kwape; Martha Chilufya; Sten H Vermund
Journal:  AIDS       Date:  2003-06-13       Impact factor: 4.177

Review 10.  Nevirapine resistance after single dose prophylaxis.

Authors:  Susan H Eshleman; J Brooks Jackson
Journal:  AIDS Rev       Date:  2002 Apr-Jun       Impact factor: 2.500

View more
  1 in total

Review 1.  Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review.

Authors:  Annabelle Gourlay; Isolde Birdthistle; Gitau Mburu; Kate Iorpenda; Alison Wringe
Journal:  J Int AIDS Soc       Date:  2013-07-19       Impact factor: 5.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.